By Pierre Bertrand

 

Bayer said that its menopause drug Elinzanetant met the primary endpoints of its Oasis 1 and 2 Phase 3 studies.

When compared with placebo, the drug showed a statistically significant reduction in the frequency and the severity of moderate to severe vasomotor symptoms, also known as hot flashes.

It also demonstrated statistically significant improvements in sleep disturbances and menopause-related quality of life, the company said.

The Oasis 1 and 2 studies assessed the efficacy and safety of Elinzanetant when administered orally once daily. The result of the Oasis 3 Phase 3 study is expected in the coming months, Bayer said.

The company added that it plans to submit the data from the Oasis studies to health authorities for marketing authorizations.

 

Write to Pierre Bertrand at pierre.bertrand@wsj.com

 

(END) Dow Jones Newswires

January 08, 2024 02:50 ET (07:50 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.
Bayer (TG:BAYN)
Gráfica de Acción Histórica
De Abr 2024 a May 2024 Haga Click aquí para más Gráficas Bayer.
Bayer (TG:BAYN)
Gráfica de Acción Histórica
De May 2023 a May 2024 Haga Click aquí para más Gráficas Bayer.